Skip to Main Content

Paper Details

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.
Pediatr Blood Cancer
26
2016
ALL, ALL xenografts, MDM2, MK-8242, MLL, MLL-rearranged xenografts, MV4;11, RS4;11, TP53, TP53 mutant, TP53 mutant cell lines, TP53 wild, TP53 wild-type cell lines, TP53 wild-type models, TP53 wild-type solid tumor xenografts, acute lymphoblastic leukemia, human, in vitro cell line panel, mice, osteosarcoma, solid tumor, solid tumors, systemic-, tumor, xenografts
Author NameAffiliation
Charles Patrick ReynoldsCancer Center, Texas Tech University Health Sciences Center
Edward A KolbA.I. duPont Hospital for Children
Richard GorlickThe Children's Hospital at Montefiore
Richard GorlickThe Children's Hospital at Montefiore
Richard B LockChildren's Cancer Institute Australia for Medical Research
Stephen T KeirDuke University Medical Center
John M MarisChildren's Hospital of Philadelphia, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute
John M MarisChildren's Hospital of Philadelphia, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute
Raushan T KurmashevaNationwide Children's Hospital
Peter J HoughtonNationwide Children's Hospital
Malcolm A Smith
Malcolm A Smith
  • 1 - 12

Datasets

Release 1.2